Repatriation Medical Authority - Notice of Investigation - Alzheimer-type Dementia

Overview

The Veterans' Entitlements Act 1986, enacted to provide various benefits to veterans and their families, was introduced to address the needs and entitlements of individuals who have served in the Australian Defence Force. The Act has since been amended to include provisions for the examination of various health issues related to military service, including mental health and physical disabilities. The Repatriation Medical Authority, an entity established under this Act, was mandated to investigate specific health concerns, such as the potential link between androgen deprivation therapy and Alzheimer-type dementia, as highlighted in Statements of Principles Instrument Nos. 22 & 23 of 2010. The Authority, exercising its powers under section 196G of the VEA, invites eligible individuals and organisations to submit written evidence to inform this investigation. The policy objective behind this investigation is to ensure that veterans' health concerns are thoroughly examined and adequately addressed within the framework of existing legislation. The Repatriation Medical Authority, acting under the direction of the Parliament of Australia, seeks to gather comprehensive input from relevant stakeholders, including veterans, their representatives, and experts in relevant fields. The Authority's initiative to investigate the potential correlation between androgen deprivation therapy and Alzheimer-type dementia aims to enhance the understanding of these health issues within the veteran community, thereby ensuring that any identified connections are appropriately recognised and managed within the veterans' entitlements system.

Scope and Application

Pursuant to section 196G of the Veterans' Entitlements Act 1986, the Repatriation Medical Authority (the Authority) has issued a notice of its intention to conduct an investigation into the potential link between androgen deprivation therapy and Alzheimer-type dementia, with a focus on its implications for veterans. This investigation is framed within the context of Statements of Principles Instrument Nos. 22 & 23 of 2010, which address Alzheimer-type dementia. The Authority extends an invitation to eligible individuals, such as those who can make a claim for pension under Part II or Part IV of the Veterans' Entitlements Act 1986, and those eligible for compensation under the Military Rehabilitation and Compensation Act 2004, as well as organisations representing veterans or their dependents, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and individuals with relevant expertise, to submit written submissions. The Authority's first meeting to discuss this investigation is scheduled for 6 December 2016, and submissions can be made electronically via the RMA website, by email, or by post, with a deadline of 2 December 2016. Submissions must be in writing, and the RMA Submission Guidelines are available online for reference. The Authority’s decision to conduct this investigation is in line with its statutory obligations and aims to ensure a comprehensive review of the matter at hand.

Key Provisions

The primary provision of this notice is section 196G of the Veterans' Entitlements Act 1986 (VEA) (196G), which informs that the Repatriation Medical Authority (the Authority) intends to carry out an investigation regarding the potential link between androgen deprivation therapy and Alzheimer-type dementia. This investigation is to be conducted in the context of Statements of Principles Instrument Nos. 22 & 23 of 2010, as amended (196B(7A)). The Authority has invited submissions from various stakeholders, including veterans and their representatives, as well as experts in relevant fields (196G). The Authority's obligations under this notice involve facilitating the investigation by soliciting and considering written submissions from the invited parties (196G). This includes providing clear guidelines for submission processes, which can be accessed through the RMA website, email, or postal mail (196G). The Authority must ensure that all submissions are received by the specified deadline of 2 December 2016 (196G). Furthermore, the Authority is required to convene its first meeting for this investigation on 6 December 2016 (196G). Failure to comply with the requirements of this notice, particularly the submission deadline, may lead to consequences for those who wish to participate in the investigation. The notice does not explicitly state penalties for non-compliance, but it is implied that missing the submission deadline would exclude a party from contributing to the investigation. The notice does not outline specific civil or criminal penalties for breaches; however, non-compliance may affect the comprehensiveness and scope of the investigation. In summary, section 196G of the VEA mandates the Authority to conduct an investigation into the potential link between androgen deprivation therapy and Alzheimer-type dementia. The Authority is obligated to invite and consider submissions from relevant parties and ensure that all submissions are received by the deadline. While the notice does not explicitly state penalties for non-compliance, missing the submission deadline would likely exclude a party from contributing to the investigation.